CD8A and neoplasm: βIg-h3 interacts with CD61 on CD8+ T cells, causing Hic-5 protein to bind to Y505-phosphorylated Lck and inhibit TCR signaling, which inhibited tumor-specific CD8+ T-cell activation (Goehrig et al., 2019).